Laura E Via Selected Research

Infections

4/2024	Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
10/2022	Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues.
9/2022	IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques.
1/2022	A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.
1/2022	E3 Ligase FBXW7 Facilitates Mycobacterium Immune Evasion by Modulating TNF-α Expression.
11/2019	Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.
10/2019	Inhibition of CorA-Dependent Magnesium Homeostasis Is Cidal in Mycobacterium tuberculosis.
11/2018	Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase.
12/2017	Host blood RNA signatures predict the outcome of tuberculosis treatment.
4/2016	Mathematical Model of Oxygen Transport in Tuberculosis Granulomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laura E Via Research Topics

Disease

48	Tuberculosis (Tuberculoses) 04/2024 - 06/2008
18	Infections 04/2024 - 06/2008
15	Granuloma 04/2024 - 06/2008
12	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2021 - 01/2010
8	Extensively Drug-Resistant Tuberculosis 01/2017 - 01/2008
5	Inflammation (Inflammations) 09/2022 - 01/2018
5	Pulmonary Tuberculosis 01/2021 - 10/2012
3	Hypoxia (Hypoxemia) 02/2024 - 02/2015
2	Atherosclerosis 03/2024 - 01/2018
2	Necrosis 02/2024 - 04/2016
2	Paramyxoviridae Infections (Parainfluenza) 12/2022 - 05/2022
2	COVID-19 10/2022 - 09/2022
2	Pneumonia (Pneumonitis) 10/2022 - 09/2022
2	Lung Diseases (Lung Disease) 01/2022 - 07/2015
2	Persistent Infection 01/2021 - 08/2012
2	Disease Progression 10/2019 - 07/2014
1	Fibrosis (Cirrhosis) 01/2023
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Ototoxicity 01/2021
1	Extrapulmonary Tuberculosis 11/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2018
1	Virus Diseases (Viral Diseases) 01/2018
1	Latent Tuberculosis 05/2015
1	Gout 05/2015
1	Neoplasms (Cancer) 02/2015

Drug/Important Bio-Agent (IBA)

8	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 12/2014
7	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 01/2012
7	FluoroquinolonesIBA 01/2017 - 01/2008
6	Isoniazid (Ftivazide)FDA LinkGeneric 01/2017 - 08/2011
5	LipidsIBA 03/2024 - 01/2012
5	Kanamycin FDA Link 01/2021 - 01/2008
5	Biomarkers (Surrogate Marker)IBA 11/2019 - 01/2012
5	Pyrazinamide FDA LinkGeneric 01/2018 - 01/2012
4	VaccinesIBA 12/2022 - 07/2014
4	AntigensIBA 10/2022 - 06/2008
4	CytokinesIBA 09/2022 - 11/2012
4	Amikacin (A.M.K)FDA LinkGeneric 01/2021 - 02/2010
4	Streptomycin (Streptomycin Sulfate)FDA Link 01/2021 - 01/2008
4	Proteins (Proteins, Gene)FDA Link 11/2019 - 07/2013
4	EnzymesIBA 10/2019 - 07/2013
4	Linezolid (Zyvox)FDA Link 11/2015 - 06/2012
3	Oxygen (Dioxygen)IBA 02/2024 - 06/2008
3	AminoglycosidesIBA 01/2021 - 02/2010
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2020 - 07/2015
3	Messenger RNA (mRNA)IBA 12/2017 - 10/2016
3	Moxifloxacin (Avelox)FDA Link 01/2017 - 03/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 07/2012
2	RNA (Ribonucleic Acid)IBA 04/2024 - 12/2017
2	Antimicrobial PeptidesIBA 04/2024 - 01/2016
2	Bevacizumab (Avastin)FDA Link 04/2024 - 02/2015
2	COVID-19 VaccinesIBA 12/2022 - 05/2022
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2010
2	EicosanoidsIBA 01/2016 - 07/2014
1	Losartan (Cozaar)FDA LinkGeneric 04/2024
1	cholesterol 25-hydroxylaseIBA 03/2024
1	CollagenIBA 01/2023
1	Coloring Agents (Dyes)IBA 01/2023
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2023
1	Viral RNAIBA 10/2022
1	InterferonsIBA 10/2022
1	Neutralizing AntibodiesIBA 09/2022
1	Interleukin-10 (Interleukin 10)IBA 09/2022
1	IgA receptor (protein B)IBA 05/2022
1	MacrolidesIBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Drug CombinationsIBA 01/2021
1	Caspase 1 (ICE Protease)IBA 01/2021
1	5- (2- oxopropylideneamino)- 6- d- ribitylaminouracilIBA 01/2021
1	Inflammation MediatorsIBA 11/2019
1	CytochromesIBA 10/2019
1	Oxidoreductases (Dehydrogenase)IBA 10/2019
1	AmidesIBA 10/2019
1	MagnesiumIBA 11/2018
1	ElementsIBA 11/2018
1	Rabies Vaccines (Rabies Vaccine)FDA Link 01/2018
1	CholesterolIBA 01/2018
1	Triglycerides (Triacylglycerol)IBA 01/2018
1	GuanineIBA 01/2017
1	Ofloxacin (Ofloxacine)FDA LinkGeneric 01/2017
1	SolutionsIBA 04/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016
1	ProteomeIBA 01/2016
1	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 11/2015
1	Citrate (si)-Synthase (Synthase, Citrate)IBA 11/2015
1	LipopolysaccharidesIBA 08/2015
1	Granzymes (Granzyme)IBA 08/2015
1	PerforinIBA 08/2015
1	Aligeron (AS 2)IBA 07/2015
1	bedaquiline (R207910)IBA 06/2015
1	Allopurinol (Remid)FDA LinkGeneric 05/2015
1	Xanthine OxidaseIBA 05/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015

Therapy/Procedure

14	Therapeutics 04/2024 - 01/2008
8	Drug Therapy (Chemotherapy) 04/2024 - 01/2010
4	Injections 01/2021 - 10/2012
3	Duration of Therapy 01/2022 - 01/2008
2	Aftercare (After-Treatment) 01/2016 - 12/2014
2	Lasers (Laser) 01/2016 - 10/2015
1	Secondary Prevention 01/2023